Terns Pharmaceuticals, Inc.(“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced findings from a Phase 1 study of TERN-701 in Western healthy volunteers. The study is an ongoing Phase 1 open-label, single ascending dose trial to evaluate the pharmacokinetics (PK), food effect, safety and tolerability of TERN-701 in healthy adults.

Terns Pharmaceuticals, Inc.（“Terns”或“公司”）（纳斯达克：TERN），一家临床阶段的生物制药公司，开发了一系列小分子候选产品，以解决包括肿瘤学和肥胖症在内的严重疾病，今天宣布了西方健康志愿者TERN-701第一阶段研究的结果。该研究是一项正在进行的1期开放标签单次递增剂量试验，旨在评估TERN-701在健康成年人中的药代动力学（PK），食物效应，安全性和耐受性。

TERN-701 is Terns’ proprietary, oral, potent, allosteric BCR-ABL inhibitor, a novel class of therapy for CML that has demonstrated superior efficacy and safety compared to traditional active-site tyrosine kinase inhibitors (TKIs). “We are pleased with the interim findings from this healthy volunteer study, which indicate TERN-701 can be administered once-daily (QD) with or without food at doses that achieve clinically efficacious exposures.

TERN-701是Terns专有的口服强效变构BCR-ABL抑制剂，是一种新型的CML治疗药物，与传统的活性位点酪氨酸激酶抑制剂（TKIs）相比，具有更高的疗效和安全性。“我们对这项健康志愿者研究的中期结果感到满意，该研究表明，TERN-701可以每天服用一次（QD），无论是否进食，剂量均可达到临床有效暴露。

TERN-701 has the potential to be a differentiated BCR-ABL inhibitor with advantages over asciminib, including more convenient dosing to improve treatment options and quality of life for people living with CML,” said Emil Kuriakose, MD, chief medical officer at Terns Pharmaceuticals.   “We are excited to see clinical PK data continuing to support once-daily dosing and new data showing lack of food.

TERN-701有可能成为一种分化的BCR-ABL抑制剂，具有优于asciminib的优势，包括更方便的剂量，以改善CML患者的治疗选择和生活质量，”Terns Pharmaceuticals首席医疗官Emil Kuriakose医学博士说。“我们很高兴看到临床PK数据继续支持每日一次的剂量，新数据显示缺乏食物。